A Preliminary Study of Risperidone in the Treatment of Posttraumatic Stress Disorder Related to Childhood Abuse in Women
The DOI matches its Crossref record.
Abstract
BACKGROUND: This study evaluated the effectiveness of risperidone in women for the treatment of posttraumatic stress disorder (PTSD) related to childhood physical, sexual, verbal, and emotional abuse. METHOD: Subjects were outpatient adult women, aged 18 to 64 years, with chronic PTSD related to childhood physical, sexual, verbal, or emotional abuse. Data were collected from November 18, 2001, to June 7, 2003. Subjects met DSM-III-R criteria for PTSD and criteria for PTSD on the Clinician-Administered PTSD Scale, 1-month version (CAPS-1). Subjects were randomly assigned to receive risperidone (N = 12) in flexible daily dosages in the range of 0.5 to 8 mg or placebo (N = 9) for 8 weeks. The primary outcome measures were changes in score from baseline on the CAPS-1 and the Clinician-Administered PTSD Scale, 1-week version (CAPS-2). RESULTS: Risperidone-treated patients had a significantly greater reduction in total score on the CAPS-2 (z = -2.44, p = .015). Risperidone-treated patients also had significantly greater reductions in the intrusive (z = -5.71, p < .001) and hyperarousal (z = -2.74, p = .006) subscale scores of the CAPS-2. CONCLUSION: The results of the current study indicate that low-dosage risperidone is a safe and effective treatment for intrusive and hyperarousal symptoms in adult women with chronic PTSD from childhood physical, sexual, verbal, and emotional abuse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Adjunctive risperidone [1039-1044] 1* Adjunctive tiagabine [1023-1025] 4”
BackgroundWhat Is a “Mood Stabilizer”? An Evidence-Based Response
Bauer, M. S., & Mitchner, L. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.3 · Cited by 862
Pharmacotherapy for post traumatic stress disorder (PTSD)
Stein, D. J., Ipser, J. C., Seedat, S., Sager, C., & Amos, T. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub2 · Cited by 519
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis
Hoskins, M., Pearce, J., Bethell, A., Dankova, L., Barbui, C., Tol, W. A., van Ommeren, M., de Jong, J., Seedat, S., Chen, H., et al. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.148551 · Cited by 418
Lee, D. J., Schnitzlein, C. W., Wolf, J. P., Vythilingam, M., Rasmusson, A. M., & Hoge, C. W. (2016) · Depression and Anxiety · doi:10.1002/da.22511 · Cited by 416
Coventry, P. A., Meader, N., Melton, H., Temple, M., Dale, H., Wright, K., Cloitre, M., Karatzias, T., Bisson, J., Roberts, N. P., et al. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003262 · Cited by 358
“The complex-trauma subgroups of the included studies were categorised as follows: post–combat deployment veterans (55 studies) [32–35, 37, 39–41, 43–48, 50–54, 56, 58, 60–63, 66–71, 73, 74, 76, 77, 82, 90, 100, 103, 104, 106–108, 115, 116, 121, 123, 124, 127, 128, 132, 133, 136, 143]; war-related (16 studies; 15 paper…”
Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic review
Berger, W., Mendlowicz, M. V., Marques-Portella, C., Kinrys, G., Fontenelle, L. F., Marmar, C. R., & Figueira, I. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.12.004 · Cited by 347
Forbes, D., Creamer, M., Phelps, A., Bryant, R., McFarlane, A., Devilly, G. J., Matthews, L., Raphael, B., Doran, C., Merlin, T., et al. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701449161 · Cited by 335
Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD)
Ipser, J. C., & Stein, D. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001209 · Cited by 216
“In a trial of 21 women with PTSD from childhood physical, sexual, verbal and emotional abuse, 8 wk risperidone treatment resulted in a significant reduction of symptom severity on CAPS-2 (Reich et al. 2004).”
BackgroundPharmacological treatment of PTSD – Established and new approaches
Steckler, T., & Risbrough, V. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.06.012 · Cited by 182
Hoskins, M. D., Bridges, J., Sinnerton, R., Nakamura, A., Underwood, J. F. G., Slater, A., Lee, M. R. D., Clarke, L., Lewis, C., Roberts, N. P., et al. (2021) · European Journal of Psychotraumatology · doi:10.1080/20008198.2020.1802920 · Cited by 127
“Six studies assessed risperidone (Bartzokis et al., 2005; Hamner et al., 2000; Krystal et al., 2011; Monnelly et al., 2003; Reich et al., 2004; Rothbaum et al., 2008), three assessed topiramate (Akuchekian & Amanat, 2004; Batki et al., 2014; Lindley et al., 2007), and two assessed d-cycloserine…”
BackgroundInfluentialCarey, P., Suliman, S., Ganesan, K., Seedat, S., & Stein, D. J. (2012) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2238 · Cited by 70
“There have been a number of trials using antipsychotics as augmentating agents but less work on these medications as monotherapy (Eidelman et al., 2000; Hamner et al., 2003; Monnelly et al., 2003; Reich et al., 2004; Bartzokis et al., 2005; Kozaric-Kovacic et al., 2005; Ipser et al., 2006; Berger et al., 2009).”
BackgroundAlbert, U., Carmassi, C., Cosci, F., De Cori, D., Di Nicola, M., Ferrari, S., Poloni, N., Tarricone, I., & Fiorillo, A. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000127 · Cited by 58
“…was first investigated in veterans with chronic psychotic PTSD, showing an effect in improving intrusive and psychotic symptoms, aggressive behaviors, and the overall PTSD symptomatology (Hamner et al., 2003; Monnelly et al., 2003; Reich et al., 2004; Bartzokis et al., 2005; Padala et al., 2006).”
BackgroundShinn, A. K., Wolff, J. D., Hwang, M., Lebois, L. A. M., Robinson, M. A., Winternitz, S. R., Öngür, D., Ressler, K. J., & Kaufman, M. L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.01011 · Cited by 31
Self-citationPsychopharmacologic Treatments for Dissociative Identity Disorder
Loewenstein, R. J. (2005) · Psychiatric Annals · doi:10.3928/00485713-20050801-08 · Cited by 16
Advances in the management of treatment-resistant anxiety disorders
Lanouette, N. M., & Stein, M. B. (2010) · Focus · doi:10.1176/foc.8.4.foc501 · Cited by 15
Metadata
- Authors
- Reich, D. B., Winternitz, S., Hennen, J., Watts, T., & Stanculescu, C.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-12-15
- Volume
- 65
- Issue
- 12
- Pages
- 1601-1606
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2056375324
- Cited by
- 119
- References
- 0
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.